XERIS BIOPHARMA HOLDINGS, INC. Increase Decrease In Operating Lease Liability
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase Decrease In Operating Lease Liability of -$911.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$477.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$434.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$422.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$412.00K, a 215.08% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.58M, a 245.93% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for fiscal 2024 was $1.08M, a 85.67% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for fiscal 2023 was $7.54M.
- XERIS BIOPHARMA HOLDINGS, INC. increase decrease in operating lease liability for fiscal 2022 was -$899.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$911.00K 10-Q · filed 2026-08-06 | -$1.33M derived: sum of 3 quarters · filed 2026-08-06 | -$1.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$434.00K 10-Q · filed 2026-05-07 | -$856.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.27M derived: sum of 3 quarters · filed 2026-05-07 | -$1.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$834.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.22M derived: sum of 3 quarters · filed 2026-08-06 | -$1.58M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$412.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$802.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.15M 10-Q · filed 2025-11-06 | -$1.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$390.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$742.00K 10-Q · filed 2026-08-06 | -$1.08M derived: sum of 3 quarters · filed 2026-08-06 | -$726.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$352.00K 10-Q · filed 2026-05-07 | -$694.00K derived: sum of 2 quarters · filed 2026-05-07 | -$336.00K derived: sum of 3 quarters · filed 2026-05-07 | -$34.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $16.00K derived: sum of 2 quarters · filed 2026-03-02 | $318.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.08M 10-K · filed 2026-03-02 |
| 2024-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $660.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.42M 10-Q · filed 2025-11-06 | $2.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.06M 10-Q · filed 2025-08-07 | $1.96M derived: sum of 3 quarters · filed 2026-03-02 | $2.64M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $762.00K 10-Q · filed 2025-05-08 | $1.66M derived: sum of 2 quarters · filed 2026-03-02 | $2.34M derived: sum of 3 quarters · filed 2026-03-02 | $8.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $893.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.58M derived: sum of 2 quarters · filed 2026-03-02 | $7.73M derived: sum of 3 quarters · filed 2026-03-02 | $7.54M 10-K · filed 2026-03-02 |
| 2023-09-30 | $684.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $6.83M derived: sum of 2 quarters · filed 2024-11-08 | $6.64M 10-Q · filed 2024-11-08 | $5.75M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $6.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.96M 10-Q · filed 2024-08-08 | $5.06M derived: sum of 3 quarters · filed 2025-03-06 | $5.06M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$188.00K 10-Q · filed 2024-05-09 | -$1.09M derived: sum of 2 quarters · filed 2025-03-06 | -$1.09M derived: sum of 3 quarters · filed 2025-03-06 | -$1.09M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$899.00K derived: sum of 2 quarters · filed 2025-03-06 | -$899.00K derived: sum of 3 quarters · filed 2025-03-06 | -$899.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |